S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
15 A.I. Trading Opportunities a Day (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
WARNING TO ALL U.S. INVESTORS (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
WARNING TO ALL U.S. INVESTORS (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
15 A.I. Trading Opportunities a Day (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
WARNING TO ALL U.S. INVESTORS (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
WARNING TO ALL U.S. INVESTORS (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
15 A.I. Trading Opportunities a Day (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
WARNING TO ALL U.S. INVESTORS (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
WARNING TO ALL U.S. INVESTORS (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
15 A.I. Trading Opportunities a Day (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
WARNING TO ALL U.S. INVESTORS (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
WARNING TO ALL U.S. INVESTORS (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
NASDAQ:ACHV

Achieve Life Sciences (ACHV) Price Target & Analyst Ratings

$6.74
+0.28 (+4.33%)
(As of 06/2/2023 ET)
Compare
Today's Range
$6.54
▼
$6.89
50-Day Range
$5.13
▼
$9.93
52-Week Range
$2.00
▼
$10.30
Volume
144,577 shs
Average Volume
264,508 shs
Market Capitalization
$121.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.67
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Achieve Life Sciences Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 2 Analyst Ratings

Consensus Analyst Price Target

$18.67
176.95% Upside
High Prediction$20.00
Average Prediction$18.67
Low Prediction$17.00
TypeCurrent
6/4/22 to 6/4/23		1 Month Ago
5/5/22 to 5/5/23		3 Months Ago
3/6/22 to 3/6/23		1 Year Ago
6/4/21 to 6/4/22
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
4 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$18.67$12.50$17.33$24.25
Predicted Upside176.95% Upside184.41% Upside324.42% Upside210.20% Upside
Get Achieve Life Sciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter.


ACHV Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ACHV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Achieve Life Sciences Stock vs. The Competition

TypeAchieve Life SciencesMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.66
2.49
Consensus RatingBuyBuyHold
Predicted Upside176.95% Upside1,263.19% Upside209.77% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/31/2023Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$22.00 ➝ $19.00+204.49%
5/10/2023Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Jason McCarthy
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetBuy$8.00 ➝ $20.00+115.75%
3/17/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOutperform$17.00+282.88%
(Data available from 6/4/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ACHV Price Target - Frequently Asked Questions

What is Achieve Life Sciences's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for Achieve Life Sciences stock is Buy based on the current 2 buy ratings for ACHV. The average twelve-month price prediction for Achieve Life Sciences is $18.67 with a high price target of $20.00 and a low price target of $17.00. Learn more on ACHV's analyst rating history.

Do Wall Street analysts like Achieve Life Sciences more than its competitors?

Analysts like Achieve Life Sciences more than other Medical companies. The consensus rating score for Achieve Life Sciences is 3.00 while the average consensus rating score for medical companies is 2.66. Learn more on how ACHV compares to other companies.

Does Achieve Life Sciences's stock price have much upside?

According to analysts, Achieve Life Sciences's stock has a predicted upside of 177.28% based on their 12-month price targets.

What analysts cover Achieve Life Sciences?

Achieve Life Sciences has been rated by Lake Street Capital, Maxim Group, and Oppenheimer in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:ACHV) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -